Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels-Reference-Cited by-同舟云学术

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

Published:2014-05-16 Issue: Volume:4 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Leung Anna M.,Lee Agnes Fermin,Ozao-Choy Junko,Ramos Romela Irene,Hamid Omid,Oâ€™Day Steven J.,Shin-Sim Myung,Morton Donald L.,Faries Mark B.,Sieling Peter A.,Lee Delphine J.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference27 articles.

1. Surgery for distant melanoma metastasis;Leung;Cancer J,2012

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells;Magistrelli;Eur J Immunol,1999

4. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement;Linsley;Immunity,1996

5. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells;Wang;Scand J Immunol,2001

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and prospects of biomarkers for immune checkpoint inhibitors;Cell Reports Medicine;2024-07

2. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade;Journal of Clinical Investigation;2024-04-01

3. Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies;Experimental & Molecular Medicine;2024-01-05

4. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome;Therapeutic Advances in Medical Oncology;2024-01

5. CTLA4 genetic variants associated with urothelial bladder cancer susceptibility;2023-12-07